TG Therapeutics initiates study of ublituximab/ PI3K Delta inhibitor combo

TG Therapeutics (TGTX +10.4%) jumps after announcing the initiation of a Phase 1 trial to test the efficacy and safety of a TG-1101/ TGR-1202 combo in relapsed and/or refractory CLL and NHL.

In other company news, TGTX opens the first expansion cohort in a TGR-1202 dose escalation study — no MTD has yet been determined. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs